Propranolol in the Treatment of Thyrotoxicosis

Abstract

ABSTRACT. Twenty‐five patients with newly diagnosed thyrotoxicosis participated in a double‐blind study of the added effect of propranolol during tiamazol treatment. During the trial, the effect of treatment was ascertained by estimation at regular intervals of the clinical score (Crooks‐Wayne index), free thyroxine index, serum triiodothyronine, serum reverse triiodothyronine, serum thyroglobulin and serum thyroglobulin antibodies. Both groups became euthyroid within two weeks. No statistically significant difference in the values for the clinical score or for any of the laboratory parameters measured was found between propranolol‐ and the placebo‐treated patients. It is concluded that propranolol has no beneficial effect on tiamazol‐treated hyper‐thyroid patients.

Short-Term Effects of β-adrenergic Antagonists and Methimazole in New-Onset Thyrotoxicosis Caused by Graves' Disease

“…They are also used in preparation for surgical management or as adjuncts to radioiodine in patients with Graves' disease (GD), the main cause of thyrotoxicosis (1,5). Although it has been established that β-blockers are effective for treating severe hyperthyroidism and thyroid storm (6), the efficacy of β-blockers as adjuncts to anti-thyroid drugs has not been proven (7).…”

Хроническая Обструктивная Болезнь Легких И Хроническая Сердечная Недостаточность: Особенности Совместной Терапии

“…Аналогичные результаты были получены в исследованиях карведилола [26] и бисопролола [27]. Кроме того, препараты этой груп пы занимают центральное место в терапии больных, перенесших инфаркт миокарда [28], у пациентов со стенокардией [29] и гипертиреозом [30]. Таким образом, большой терапевтический потенциал β бло каторов является серьезным аргументом для их ис пользования у больных ХОБЛ с сопутствующими сер дечно сосудистыми заболеваниями.…”

Use of blockers in patients with COPD

“…The strongest evidence for the mortality benefit of β blockers is in myocardial infarction,6 – 8 ischaemia8 and left ventricular systolic dysfunction,9 10 but there are a number of other settings including hypertension,11 – 13 tachyarrhythmia,14 perioperative risk modification15 16 and thyrotoxicosis 17 – 19. Although there are many potential explanations for the reduction in mortality, the benefit is clear.…”